RED CELL THERAPEUTICS
LIVE

Serial Number

88807844

Owner

Rubius Therapeutics, Inc.

Attorney

Christina M. Licursi

First Use Date

Nov 11, 2020

Filing Date

Feb 24, 2020

Add to watchlist:

No watchlists yet
View on USPTO

RED CELL THERAPEUTICS Trademark

Serial Number: 88807844 • Registration: 6532454

RED CELL THERAPEUTICS is a trademark filed by Rubius Therapeutics, Inc. on February 24, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Rubius Therapeutics, Inc. (10 trademarks)

Cambridge, MA 02139

Entity Type: 03

Trademark Details

Filing Date

February 24, 2020

Registration Date

October 19, 2021

First Use Anywhere

November 11, 2020

First Use in Commerce

November 11, 2020

Goods & Services

Cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; pharmaceutical preparations of engineered erythroid cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; engineered erythroid cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; none of the foregoing used as vitamin-mineral supplements or for animals

Filing History

REGISTERED-SUPPLEMENTAL REGISTER
Oct 19, 2021 R.SR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 15, 2021 PREV
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Sep 7, 2021 CNTA
EXAMINER'S AMENDMENT ENTERED
Sep 7, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 7, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 7, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 7, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 21, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 20, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 20, 2021 TROA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Feb 9, 2021 AAUA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 6, 2021 GNRN
NON-FINAL ACTION E-MAILED
Feb 6, 2021 GNRT
NON-FINAL ACTION WRITTEN
Feb 6, 2021 CNRT
USE AMENDMENT ACCEPTED
Feb 6, 2021 IUAA
AMENDMENT TO USE PROCESSING COMPLETE
Jan 12, 2021 AUPC
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 20, 2020 TEME
USE AMENDMENT FILED
Nov 19, 2020 IUAF
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 19, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 19, 2020 TROA
TEAS AMENDMENT OF USE RECEIVED
Nov 19, 2020 EAAU
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 20, 2020 GNRN
NON-FINAL ACTION E-MAILED
May 20, 2020 GNRT
NON-FINAL ACTION WRITTEN
May 20, 2020 CNRT
ASSIGNED TO EXAMINER
May 13, 2020 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Mar 21, 2020 AMPX
ASSIGNED TO LIE
Mar 13, 2020 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Mar 6, 2020 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 27, 2020 NWOS
NEW APPLICATION ENTERED
Feb 27, 2020 NWAP